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Sir,
We have previously reported that CA IX (a marker of hypoxia) is
an independent prognostic marker in early-stage breast cancer
(Hussain et al, 2007).
A letter from Span et al in this issue questions whether CA IX is
in fact a predictive factor for reduced benefit from adjuvant
therapy rather than a prognostic factor. This is based on their own
report of 253 patient series published previously (Span et al, 2003).
Following the submission of our manuscript, a further publication
has supported the conclusion that CA IX is a marker of poor
prognosis in premenopausal breast cancer patients and it is an
independent predictor of survival in patients with one to three
lymph nodes (Brennan et al, 2006).
Within our patient cohort, those with ER-positive tumours
received adjuvant endocrine therapy (mostly tamoxifen). Taking
this into account, CA IX remained an independent prognostic
factor.
Data regarding adjuvant chemotherapy were available for 126 of
the 144 patients. Of these, 39 received adjuvant chemotherapy
(mostly CMF). Of 31 patients with CA IX positivity and available
data, only nine received adjuvant chemotherapy. Thus, based on
these numbers, we are unable to draw conclusions regarding a
predictive role for CA IX and benefit from adjuvant chemotherapy.
We certainly agree that the potential predictive value of CA IX in
determining the most appropriate adjuvant therapy is interesting
and reiterate our concluding remarks:
‘yCA IX expression may serve as a predictive factor to guide
the selection of the most appropriate adjuvant treatment modality’
and: ‘Randomised studies with translational endpoints are
required to further elucidate the prognostic and predictive value
of CA IX’.
The comments by Span et al suggesting that CA IX-positive
patients derive little or no benefit from standard treatments raise
the important question whether these patients should therefore
receive no treatment, or are actually candidates for targeting with
potentially more effective treatment. We recognise that the utility
of CA IX expression is currently experimental and the issue of both
prognostic and predictive status will only be clearly resolved when
investigated in a large series of patients treated within randomised
trials of different therapies.
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